Genetic Ophthalmology Disorders Drug Development Pipeline Review, 2017 Market Report; Launched via MarketResearchReports.com

248
0
SHARE

Lewes, DE — 01/15/2018 — Genetic Ophthalmology Disorders Drug Development Pipeline Review, 2017 report provides an overview of the pipeline landscape for genetic ophthalmological disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Stargardt disease, Leber congenital amaurosis, Leber's hereditary optic neuropathy, Usher Syndrome and Retinitis pigmentosa, and features dormant and discontinued projects.

Juvenile macular degeneration is a series of inherited eye disorders that affects children and young adults, with the most common form being Stargardt disease, an inherited autosomal recessive syndrome. Leber congenital amaurosis primarily affects the retina, which is the specialized tissue at the back of the eye that detects light and color.

It is the most common cause of inherited blindness in childhood. Leber's hereditary optic neuropathy usually begins in a person's teens or twenties, rare cases may appear in early childhood or later in adulthood. Usher syndrome is characterized by hearing impairment and progressive vision loss. The major symptoms of Usher syndrome are hearing loss and secondary retinitis pigmentosa. Finally, retinitis pigmentosa refers to a group of diseases which cause a slow but progressive vision loss. Symptoms include night blindness and loss of peripheral vision.

The size of these pipelines ranges from six products in Usher syndrome to 54 in retinitis pigmentosa. Gene therapies represent the most common type of therapy among these diseases, followed by small molecules. This reflects the therapeutic aim of repairing the defective gene in order to correct the patient's phenotype. Likewise, the molecular targets which are acted on are typically clustered around the causative gene within each disease, although there are exceptions. Within retinitis pigmentosa in particular, there is a diversity of molecular targets.

Scope
– Which companies are the most active within the pipeline for genetic ophthalmological disorder therapeutics?
– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
– What are the most important R&D milestones and data publications to have happened in the field of genetic ophthalmological disorders?

Reasons to buy
– Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
– Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
– Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
– Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Spanning over 138 pages “Genetic Ophthalmology Disorders Drug Development Pipeline Review, 2017” report covers Executive Summary, Introduction, Genetic Ophthalmology Disorders Report Coverage, Therapeutics Development, Therapeutics Assessment, Companies Involved in Therapeutics Development, Dormant Projects, Appendix.

Please visit this link for more details: https://www.marketresearchreports.com/gbi-research/genetic-ophthalmology-disorders-drug-development-pipeline-review-2017

Find all Pharma and Healthcare Reports at: https://www.marketresearchreports.com/pharma-healthcare

Related Reports;

Frontier Pharma: Liver Cancer – Identifying and Commercializing First-in-Class Innovation – Visit at – https://www.marketresearchreports.com/gbi-research/frontier-pharma-liver-cancer-identifying-and-commercializing-first-class-innovation

Frontier Pharma: Hematological Disorders – Iron Regulators and Immune Response Targeted Programs Within Anemias and other Red Blood Cell Disorders Hold Potential to Transform Therapy Area with Significant Unmet Need – Visit at – https://www.marketresearchreports.com/gbi-research/frontier-pharma-hematological-disorders-iron-regulators-and-immune-response-targeted

About Market Research Reports, Inc.
Market Research Reports® Inc. is world's largest store offering quality market research, SWOT analysis, competitive intelligence and industry reports. We help Fortune 500 to Start-Ups with the latest market research reports on global & regional markets which comprise key industries, leading market players, new products and latest industry analysis & trends.

Contact us for your market research requirements: http://www.marketresearchreports.com/contact

Powered by WPeMatico